|
September 1st, 2005
BioForce’s BioMolecular Nanoplacement System
Selected for Nanomaterial Development
North Carolina State University (NCSU) has selected the
NanoArrayer System from BioForce Nanosciences for use in the laboratory of Dr. Dan Feldheim, Professor of Chemistry.
The system is expected to be used at the facility for research into RNA sequences that can act as catalysts for the formation
of nanomaterials. Noting that BioForce will be part of the research effort at NCSU was Dr. Eric Henderson, CEO at BioForce
Nanosciences, "The NanoArrayer System provides a unique solution to the problem Dr. Feldheim faces of ultramicro-scale deposition
of femtoliter volumes on specialized surfaces developed in his laboratory. In addition to providing this technology, we will
also be working with this research group at a collaborative level as they further develop their powerful and novel molecular
screening process."
Dr. Feldheim and a team of researchers, which included
Professor Bruce Eaton at The University of Colorado, recently discovered that RNA sequences can act as central catalytic forces
used in the formation of metallic nanomaterials. It was also indicated that these new nanomaterials could be useful in the
fields of alternative energy and medical imaging. As well, according to Dr. Curtis Mosher, Vice President of Research and
Development at BioForce, "This technology has significant market potential in several areas including Molecular Diagnostics,
Molecular Detection and Pharma Discovery."
August 29th, 2005
Apparently encouraged by its recent success with Boston Scientific,
Biophan Technologies, Inc. (OTCBB: BIPH), a company involved with medical imaging technology, has formed the Biophan Business
Development Group. The group’ focus is the licensing of Biophan’s intellectual property, which includes 144 patents,
license and application related to magnetic resonance imaging and drug elution systems. Backing the group is a financing facility
of up to $30 million - to be made available through SBI Brightline XI, LLC.
John Lanzafame, President of the Nanolution drug delivery division
at Biophan, has been made Corporate Vice President of the new group. He is currently looking to fill positions for the new
group’s sales efforts
August 18th, 2005
VisEn Medical, an In Vivo Optical
Molecular Imaging Company, Raises $4 Million
VisEn has raised $4 million of venture capital through
investments from Flagship Ventures Bollard Group and other existing investors. VisEn plans to use the funds to bring its molecular
optical imaging products to market.
With the announcement of the investment, Kirtland G.
Poss, President and CEO spoke of the company’s successes so far, "In the first half of 2005, we conducted a very successful
pre-launch program, selling a pre-commercial version of our tomographic optical imaging system to three top-tier pharmaceutical
companies and two leading academic institutions in the United States and in Europe. These five sites and about 20 additional
pharmaceutical and academic customers have begun to purchase our line of molecular imaging probes. We are now positioned to
launch the commercial version of our imaging system and to expand the sales and marketing of our probes later this year. We
also will continue to work closely with our customers and partners to develop additional applications and products based on
our powerful core technologies and competencies," he continued.
VisEn's Fluorescent Molecular Tomography (FMT) system
and optical probe product line, based on near infrared light are used in vivo to generate molecular maps of disease activities.
The company’s technology is credited with enabling not only anatomic imaging but also the imaging of biological processes
at the molecular level – a current trend in the medical and medical research industries. The company’s technology,
referred to as applied imaging, enables the real time imaging of disease progression and gives a much closer look at the real
time in vivo effectiveness of drug and other treatments. The company indicates that initially the technology is intended for
small animals.
ViSen’s technology is based on technology developed
at the Center for Molecular Imaging Research at the Massachusetts General Hospital.
August 15th, 2005
Boston Scientific makes $5.0
million Investment in Biophan
Biophan Technologies, Inc. (OTCBB: BIPH) has received
$5.75 million in investments and licensing payments from Boston Scientific. The investment was in the form of a $5,000,000
purchase of Biophan’s common stock. Another $750,000 was an upfront license fee related to Biophan’s magnetic
resonance imaging safety and image compatibility technologies.
Biophan’s CEO Michael Weiner noted that the investment
would help the company’s R&D efforts, "These initial funds received through our agreements with Boston Scientific
will enable us to substantially accelerate our research and development to continue our business strategy to develop vital
new products and solutions. Boston Scientific was the first major manufacturer of advanced biomedical devices to show serious
interest in our next-generation technology solutions, which have applications across several of Boston Scientific product
lines. We are particularly excited and gratified to see Biophan's solutions validated, and look forward to their implementation
by one of the world's most innovative medical device manufacturers."
August 15th, 2005
Xenogen Enters into $15 Million
Definitive Agreement
Xenogen Corporation (NASDAQ:XGEN), a company that
develops in vivo biophotonic technology, has entered into definitive agreements to sell $15 million of its common stock and
warrants. The company indicated that the securities are being sold to institutional and venture investors.
In vivo biophotonic technology is used to non-invasively
study the cellular biology within actual living animals.
|
